What the FDA labels say about taking them together
Digoxin and potassium phosphate dibasic/potassium phosphate monobasic
Potassium phosphate dibasic/potassium phosphate monobasic's FDA label of December 31, 2024 names digoxin in its drug interactions section; the digoxin labels PlainMeds reads (3) do not name potassium phosphate dibasic/potassium phosphate monobasic. The potassium phosphate dibasic/potassium phosphate monobasic label: “Products that Increase Serum Potassium Administration of potassium phosphates injection to patients treated concurrently or recently with products that increase serum potassium increases the risk of severe and …”
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the potassium phosphate dibasic/potassium phosphate monobasic FDA label on DailyMed (effective December 31, 2024, Amneal Pharmaceuticals Private Limited).
What does the digoxin label say about potassium phosphate dibasic/potassium phosphate monobasic?
Digoxin's label (effective December 5, 2024) and its 2 other brand-application labels do not name potassium phosphate dibasic/potassium phosphate monobasic in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What does the potassium phosphate dibasic/potassium phosphate monobasic label say about digoxin?
Potassium phosphate dibasic/potassium phosphate monobasic label, drug interactionsProducts that Increase Serum Potassium Administration of potassium phosphates injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3) ].
Source: FDA drug label (Potassium Phosphates, NDA218343), Amneal Pharmaceuticals LLC, effective September 1, 2025 (SPL set dce22c93-aa48-48a9-ac8b-716400d33c9e), via openFDA
Source: FDA drug label (POTASSIUM PHOSPHATES), Amneal Pharmaceuticals Private Limited, effective December 31, 2024 (SPL set 89136c51-a60b-4269-bd05-9489f060a734), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Digoxin | Potassium phosphate dibasic/potassium phosphate monobasic | |
|---|---|---|
| Labeled for | Heart failure, Atrial fibrillation | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.133 per tablet 125 mcg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once